Last reviewed · How we verify
NCT03327493: ADRECMO
Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO
NA trial testing Biological in Shock, Cardiogenic in 48 participants. Completed in 24 May 2022.
24 May 2022
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 48 |
| Start date | 10 October 2017 |
| Primary completion | 24 May 2022 |
| Estimated completion | 24 May 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Biological — full drug profile →
Conditions studied
- Shock, Cardiogenic — all drugs for Shock, Cardiogenic →
- Extra-Corporeal-Life-Support ( ECLS) — all drugs for Extra-Corporeal-Life-Support ( ECLS) →
- Autonomic Nervous System Diseases — all drugs for Autonomic Nervous System Diseases →
- Inflammation — all drugs for Inflammation →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, any sex, with Shock, Cardiogenic or Extra-Corporeal-Life-Support ( ECLS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Refractory cardiogenic shock is characterized by a decreased in cardiac output with hypo-responsiveness to increasing doses of catecholamines resulting in a profound tissular ischemia. VAECMO, by restoring a circulatory flow, could be associated to a major reperfusion syndrome which may lead some patients to multiple organ failures and death. Pathophysiology of this syndrome includes 1/an hyper-adrenergic state secondary to the over activation of the sympathetic system and 2/ a major release of pro-inflammatory cytokines. As adrenoreceptors are also exhibited on immunes cells, the pro-inflammatory state might be enhanced by the over-activation of the sympathetic system.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults: A Health Technology Assessment.
Ontario Health (Quality) . · · 2020 · cited 8× · PMID 32284771
Verify or expand the search:
- PubMed search for NCT03327493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biological
Trials testing the same drug.
- NCT06444503 — Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies · recruiting
- NCT05893693 — Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia · NA · unknown
- NCT05608148 — Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors · Phase 1 · recruiting
- NCT05207371 — Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC · Phase 1, PHASE2 · unknown
- NCT04542967 — Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease · Phase 2 · completed
Other recruiting trials for Shock, Cardiogenic
Currently open trials in the same condition.
- NCT06832722 — Procizumab (PCZ; AK1967) in Critical Cardiovascular Care · Phase 1, PHASE2 · recruiting
- NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
- NCT06766006 — ECMO LEft Ventricle UNloading Strategy · recruiting
- NCT05669183 — Hemodynamic Comparison of Peripheral and Central VA ECMO. · recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03327493 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 19 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03327493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing